Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12259091 | 0.89 | SIGMAR1 (0.48) | HTR1AKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL14079956 | 0.85 | HTR1A (0.52) | HTR1AKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL11948184 | 0.83 | ATM (0.52) | KMT2ASMN1; SMN2NAMPTTDP1KDM4E | |
| SCHEMBL18830602 | 0.83 | ATM (0.58) | KMT2ASMN1; SMN2NAMPTTDP1KDM4E | |
| SCHEMBL14079955 | 0.83 | HTR1A (0.46) | HTR1AKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL14079939 | 0.82 | KMT2A (0.41) | HTR1AKMT2AHTTSMN1; SMN2TDP1 | |
| SCHEMBL3918700 | 0.82 | ATM (0.56) | KMT2AHTTSMN1; SMN2NAMPTTDP1 | |
| SCHEMBL12141608 | 0.81 | HSD11B1 (0.53) | KMT2ANAMPTTDP1KDM4EMEN1 | |
| SCHEMBL13601664 | 0.80 | DNM1 (0.46) | HTR1AKMT2AHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL2481091 | 0.80 | NPC1 (0.41) | KMT2ASMN1; SMN2NAMPTTDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20180015120-A1 | Self-assembling monomers and oligomers as surface-modifying endgroups for polymers | DSM IP ASSETS BV (NL) | 2018-01-18 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8829012-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | HTR1A 4133/4885KMT2A 1422/4885HTT 2485/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HTR1A 2573/4885KMT2A 1448/4885HTT 4246/4885 |
| US-20180015120-A1 | Self-assembling monomers and oligomers as surface-modifying endgroups for polymers | MLX, SRRM2, LIMA1 | HTR1A 1110/4885KMT2A 4068/4885HTT 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.